SUPPLEMENT
Q3 2024 — Financial disclosures
Q3 2024PDF · 10 pages1.1 MB
Merck & Co., Inc. Financial Highlights Package Third Quarter 2024 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 3Q24 and Sept YTD 24.......3 Table 2b: GAAP to Non-GAAP Reconciliation 3Q23 and Sept YTD 23.......4 Table 3: Sales - Current Year and Prior Year by Quarter..........................5 Table 3a: Sales – U.S. / International 3Q24................................................6 Table 3b: Sales – U.S. / International Sept YTD 24.. .................................7 Table 3c: Sales – Pharmaceutical Geographic Split...................................8 Table 4: Other (Income) Expense ............................................................9 -- 1 of 10 -- Sales 16,657 $ 15,962 $ 4% 48,544 $ 45,485 $ 7% Costs, Expenses and Other Cost of sales 4,080 4,264 -4% 11,365 12,214 -7% Selling, general and administrative 2,731 2,519 8% 7,952 7,700 3% Research and development 5,862 3,307 77% 13,354 20,904 -36% Restructuring costs 56 126 -56% 258 344 -25% Other (income) expense, net (162) 126 * (151) 388 * Income Before Taxes 4,090 5,620 -27% 15,766 3,935 * Taxes on Income 929 870 2,377 2,332 Net Income 3,161 4,750 -33% 13,389 1,603 * Less: Net Income Attributable to Noncontrolling Interests 4 5 15 12 Net Income Attributable to Merck & Co., Inc. 3,157 $ 4,745 $ -33% 13,374 $ 1,591 $ * Earnings per Common Share Assuming Dilution 1.24 $ 1.86 $ -33% 5.26 $ 0.62 $ * Average Shares Outstanding Assuming Dilution 2,541 2,546 2,543 2,549 Tax Rate 22.7% 15.5% 15.1% 59.3% * 100% or greater GAAP % Change 3Q24 3Q23 GAAP % Change Sep YTD 2024 Sep YTD 2023 MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 1 -- 2 of 10 -- Sales 15,775 $ 16,112 $ 16,657 $ 48,544 $ 14,487 $ 15,035 $ 15,962 $ 45,485 $ 14,630 $ 60,115 $ 4% 7% Costs, Expenses and Other Cost of sales 3,540 3,745 4,080 11,365 3,926 4,024 4,264 12,214 3,911 16,126 -4% -7% Selling, general and administrative 2,483 2,739 2,731 7,952 2,479 2,702 2,519 7,700 2,804 10,504 8% 3% Research and development 3,992 3,500 5,862 13,354 4,276 13,321 3,307 20,904 9,628 30,531 77% -36% Restructuring costs 123 80 56 258 67 151 126 344 255 599 -56% -25% Other (income) expense, net (33) 42 (162) (151) 89 172 126 388 78 466 * * Income (Loss) Before Taxes 5,670 6,006 4,090 15,766 3,650 (5,335) 5,620 3,935 (2,046) 1,889 -27% * Income Tax Provision (Benefit) 903 545 929 2,377 825 637 870 2,332 (821) 1,512 Net Income (Loss) 4,767 5,461 3,161 13,389 2,825 (5,972) 4,750 1,603 (1,225) 377 -33% * Less: Net Income Attributable to Noncontrolling Interests 5 6 4 15 4 3 5 12 1 12 Net Income (Loss) Attributable to Merck & Co., Inc. 4,762 $ 5,455 $ 3,157 $ 13,374 $ 2,821 $ (5,975) $ 4,745 $ 1,591 $ (1,226) $ 365 $ -33% * Earnings (Loss) per Common Share Assuming Dilution (1) 1.87 $ 2.14 $ 1.24 $ 5.26 $ 1.11 $ (2.35) $ 1.86 $ 0.62 $ (0.48) $ 0.14 $ -33% * Average Shares Outstanding Assuming Dilution (1) 2,544 2,544 2,541 2,543 2,551 2,539 2,546 2,549 2,533 2,547 Tax Rate 15.9% 9.1% 22.7% 15.1% 22.6% -11.9% 15.5% 59.3% 40.1% 80.0% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Because the company recorded a net loss in the second quarter and the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. 2024 2Q 3Q Sep YTD 1Q 1Q 2Q 3Q 4Q Full Year 2023 Sep YTD Sep YTD % Change Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF OPERATIONS - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 3Q 2 -- 3 of 10 -- Third Quarter Cost of sales 4,080 $ 639 192 831 3,249 $ Selling, general and administrative 2,731 43 31 74 2,657 Research and development 5,862 24 24 5,838 Restructuring costs 56 56 56 – Other (income) expense, net (162) (27) 58 31 (193) Income Before Taxes 4,090 (679) (279) (58) (1,016) 5,106 Income Tax Provision (Benefit) 929 (129) (3) (46) (3) (13) (3) (188) 1,117 Net Income 3,161 (550) (233) (45) (828) 3,989 Net Income Attributable to Merck & Co., Inc. 3,157 (550) (233) (45) (828) 3,985 Earnings per Common Share Assuming Dilution 1.24 $ (0.22) (0.09) (0.02) (0.33) 1.57 $ Tax Rate 22.7% 21.9% Sep YTD Cost of sales 11,365 $ 1,708 374 2,082 9,283 $ Selling, general and administrative 7,952 88 67 155 7,797 Research and development 13,354 60 2 62 13,292 Restructuring costs 258 258 258 – Other (income) expense, net (151) (48) (107) (155) 4 Income Before Taxes 15,766 (1,808) (701) 107 (2,402) 18,168 Income Tax Provision (Benefit) 2,377 (350) (3) (118) (3) 23 (3) (259) (4) (704) 3,081 Net Income 13,389 (1,458) (583) 84 259 (1,698) 15,087 Net Income Attributable to Merck & Co., Inc. 13,374 (1,458) (583) 84 259 (1,698) 15,072 Earnings per Common Share Assuming Dilution 5.26 $ (0.57) (0.23) 0.03 0.10 (0.67) 5.93 $ Tax Rate 15.1% 17.0% Only the line items that are affected by non-GAAP adjustments are shown. MERCK & CO., INC. THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Table 2a Certain Other Items Adjustment Subtotal Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets and Animal Health intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (4) Represents a benefit due to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to the 2019 federal tax return year. (3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. 3 -- 4 of 10 -- Third Quarter Cost of sales 4,264 $ 552 33 585 3,679 $ Selling, general and administrative 2,519 17 40 57 2,462 Research and development 3,307 10 10 3,297 Restructuring costs 126 126 126 – Other (income) expense, net 126 (24) 17 (7) 133 Income Before Taxes 5,620 (555) (199) (17) (771) 6,391 Income Tax Provision (Benefit) 870 (53) (4) (32) (4) (4) (4) (89) 959 Net Income 4,750 (502) (167) (13) (682) 5,432 Net Income Attributable to Merck & Co., Inc. 4,745 (502) (167) (13) (682) 5,427 Earnings per Common Share Assuming Dilution 1.86 $ (0.20) (0.07) – (0.27) 2.13 $ Tax Rate 15.5% 15.0% Sep YTD Cost of sales 12,214 $ 1,564 94 1,658 10,556 $ Selling, general and administrative 7,700 62 93 155 7,545 Research and development 20,904 29 1 30 20,874 Restructuring costs 344 344 344 – Other (income) expense, net 388 (12) (218) 573 (3) 343 45 Income Before Taxes 3,935 (1,643) (532) 218 (573) (2,530) 6,465 Income Tax Provision (Benefit) 2,332 (249) (4) (88) (4) 47 (4) (60) (4) (350) 2,682 Net Income 1,603 (1,394) (444) 171 (513) (2,180) 3,783 Net Income Attributable to Merck & Co., Inc. 1,591 (1,394) (444) 171 (513) (2,180) 3,771 Earnings per Common Share Assuming Dilution 0.62 $ (0.55) (0.18) 0.07 (0.20) (0.86) 1.48 $ Tax Rate 59.3% 41.5% Only the line items that are affected by non-GAAP adjustments are shown. Adjustment Subtotal Non-GAAP MERCK & CO., INC. THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 GAAP TO NON-GAAP RECONCILIATION (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, primarily reflect royalty income, partially offset by an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the nine-month period includes a $37 million loss on the sale of a business. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation. (4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. 4 -- 5 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 2024 2023 3Q Sep YTD 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $15,775 $16,112 $16,657 $48,544 $14,487 $15,035 $15,962 $45,485 4 7 7 10 PHARMACEUTICAL 14,006 14,408 14,943 43,358 12,721 13,457 14,263 40,442 5 8 7 10 Oncology Keytruda 6,947 7,270 7,429 21,646 5,795 6,271 6,338 18,403 17 21 18 22 Alliance Revenue – Lynparza (2) 292 317 337 947 275 310 299 884 13 13 7 8 Alliance Revenue – Lenvima (2) 255 249 251 755 232 242 260 734 -3 -4 3 3 Welireg 85 126 139 349 42 50 54 146 156 157 138 139 Alliance Revenue – Reblozyl (3) 71 90 100 261 43 47 52 142 91 91 84 84 Vaccines (4) Gardasil/Gardasil 9 2,249 2,478 2,306 7,032 1,972 2,458 2,585 7,015 -11 -10 - 3 ProQuad/M-M-R II/Varivax 570 617 703 1,891 528 582 713 1,823 -1 -1 4 4 Vaxneuvance 219 189 239 647 106 168 214 488 12 13 33 34 RotaTeq 216 163 193 572 297 131 156 584 24 25 -2 -1 Pneumovax 23 61 59 68 188 96 92 140 327 -51 -51 -42 -40 Hospital Acute Care Bridion 440 455 420 1,315 487 502 424 1,413 -1 - -7 -6 Prevymis 174 188 208 570 129 143 157 430 32 36 33 36 Dificid 73 92 96 261 65 76 74 215 31 31 21 21 Zerbaxa 56 62 64 182 50 54 53 157 22 25 16 19 Noxafil 56 45 41 141 60 55 51 167 -20 -13 -15 -5 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 98 106 102 306 99 68 92 259 11 11 18 18 Winrevair 70 149 219 - - - - Adempas (6) 70 72 72 214 59 65 65 189 11 13 13 15 Virology Lagevrio 350 110 383 843 392 203 640 1,236 -40 -36 -32 -27 Isentress/Isentress HD 111 89 102 302 123 136 119 377 -14 -10 -20 -16 Delstrigo 56 60 65 180 44 50 54 148 21 25 22 26 Pifeltro 42 39 42 123 34 38 37 109 14 15 13 14 Neuroscience Belsomra 46 53 78 177 56 63 58 176 35 40 - 7 Immunology Simponi 184 172 189 545 180 180 179 539 5 7 1 2 Remicade 39 35 41 115 51 48 45 144 -9 -5 -20 -16 Diabetes (7) Januvia 419 405 278 1,102 551 511 581 1,642 -52 -49 -33 -30 Janumet 251 224 204 679 329 354 255 937 -20 -13 -28 -23 Other Pharmaceutical (8) 576 573 644 1,796 626 560 568 1,758 13 15 2 5 ANIMAL HEALTH 1,511 1,482 1,487 4,480 1,491 1,456 1,400 4,347 6 11 3 7 Livestock 850 837 886 2,573 849 807 874 2,530 1 7 2 7 Companion Animal 661 645 601 1,907 642 649 526 1,817 14 17 5 7 Other Revenues (9) 258 222 227 706 275 122 299 696 -24 -22 2 4 Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (7) Total Diabetes sales were $745 million, $715 million and $592 million in the first, second and third quarter of 2024, respectively, and $950 million, $951 million and $924 million in the first, second and third quarter of 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61 million, $15 million and $15 million in the first, second and third quarter of 2024, respectively, and $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,424 million, $3,656 million and $3,675 million in the first, second and third quarter of 2024, respectively, and $3,133 million, $3,557 million and $4,002 million in the first, second and third quarter of 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (6) Net product sales in Merck's marketing territories. 5 -- 6 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES THIRD QUARTER 2024 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International 3Q 2024 3Q 2023 % Change 3Q 2024 3Q 2023 % Change 3Q 2024 3Q 2023 % Change TOTAL SALES (1) $16,657 $15,962 4 $8,736 $7,715 13 $7,922 $8,247 -4 PHARMACEUTICAL 14,943 14,263 5 8,227 7,153 15 6,717 7,110 -6 Oncology Keytruda 7,429 6,338 17 4,500 3,795 19 2,929 2,543 15 Alliance Revenue – Lynparza (2) 337 299 13 161 153 5 177 146 21 Alliance Revenue – Lenvima (2) 251 260 -3 173 160 9 78 100 -22 Welireg 139 54 156 127 51 148 12 3 * Alliance Revenue – Reblozyl (3) 100 52 91 82 43 93 18 10 83 Vaccines (4) Gardasil/Gardasil 9 2,306 2,585 -11 1,020 838 22 1,285 1,746 -26 ProQuad/M-M-R II/Varivax 703 713 -1 572 567 1 131 146 -10 Vaxneuvance 239 214 12 137 182 -25 103 33 * RotaTeq 193 156 24 131 108 21 62 48 28 Pneumovax 23 68 140 -51 19 42 -54 49 98 -50 Hospital Acute Care Bridion 420 424 -1 339 265 28 81 159 -49 Prevymis 208 157 32 101 70 43 107 87 24 Dificid 96 74 31 83 69 20 13 5 190 Zerbaxa 64 53 22 39 29 34 26 24 6 Noxafil 41 51 -20 1 4 -85 40 47 -15 Cardiovascular Winrevair 149 - 147 - 3 - Alliance Revenue - Adempas/Verquvo (5) 102 92 11 96 96 -1 7 -4 * Adempas (6) 72 65 11 72 65 11 Virology Lagevrio 383 640 -40 84 - 299 640 -53 Isentress/Isentress HD 102 119 -14 54 58 -6 48 61 -21 Delstrigo 65 54 21 15 13 15 50 40 23 Pifeltro 42 37 14 31 27 12 12 10 20 Neuroscience Belsomra 78 58 35 20 23 -12 58 35 66 Immunology Simponi 189 179 5 189 179 5 Remicade 41 45 -9 41 45 -9 Diabetes (7) Januvia 278 581 -52 67 328 -80 211 252 -16 Janumet 204 255 -20 15 43 -67 190 211 -10 Other Pharmaceutical (8) 644 568 13 213 189 13 426 381 12 ANIMAL HEALTH 1,487 1,400 6 487 462 6 999 938 6 Livestock 886 874 1 194 205 -5 692 669 3 Companion Animal 601 526 14 293 257 14 307 269 14 Other Revenues (9) 227 299 -24 22 100 -78 206 199 4 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $592 million and $924 million on a global basis in the third quarter of 2024 and 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $15 million and $65 million on a global basis in the third quarter of 2024 and 2023, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $3,675 million and $4,002 million on a global basis in the third quarter of 2024 and 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 6 -- 7 of 10 -- MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES SEPTEMBER YEAR-TO-DATE 2024 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International Sep YTD 2024 Sep YTD 2023 % Change Sep YTD 2024 Sep YTD 2023 % Change Sep YTD 2024 Sep YTD 2023 % Change TOTAL SALES (1) $48,544 $45,485 7 $24,089 $21,393 13 $24,455 $24,092 2 PHARMACEUTICAL 43,358 40,442 7 22,563 19,840 14 20,795 20,602 1 Oncology Keytruda 21,646 18,403 18 13,031 11,142 17 8,614 7,261 19 Alliance Revenue – Lynparza (2) 947 884 7 449 439 2 498 445 12 Alliance Revenue – Lenvima (2) 755 734 3 523 476 10 233 258 -10 Welireg 349 146 138 320 141 128 29 6 * Alliance Revenue – Reblozyl (3) 261 142 84 215 108 99 45 33 36 Vaccines (4) Gardasil/Gardasil 9 7,032 7,015 - 2,045 1,718 19 4,988 5,297 -6 ProQuad/M-M-R II/Varivax 1,891 1,823 4 1,500 1,435 5 391 388 1 Vaxneuvance 647 488 33 397 423 -6 251 65 * RotaTeq 572 584 -2 388 381 2 185 203 -9 Pneumovax 23 188 327 -42 36 105 -66 152 223 -32 Hospital Acute Care Bridion 1,315 1,413 -7 1,020 841 21 296 572 -48 Prevymis 570 430 33 265 186 43 305 244 25 Dificid 261 215 21 231 199 16 30 16 93 Zerbaxa 182 157 16 106 86 23 77 71 8 Noxafil 141 167 -15 9 29 -69 132 138 -4 Cardiovascular Alliance Revenue - Adempas/Verquvo (5) 306 259 18 283 249 14 22 10 123 Winrevair 219 - 216 - 3 - Adempas (6) 214 189 13 214 189 13 Virology Lagevrio 843 1,236 -32 144 - 699 1,236 -43 Isentress/Isentress HD 302 377 -20 147 165 -11 155 212 -27 Delstrigo 180 148 22 42 37 13 139 110 26 Pifeltro 123 109 13 86 78 10 37 31 20 Neuroscience Belsomra 177 176 - 53 60 -11 124 117 6 Immunology Simponi 545 539 1 545 539 1 Remicade 115 144 -20 115 144 -20 Diabetes (7) Januvia 1,102 1,642 -33 428 842 -49 674 800 -16 Janumet 679 937 -28 70 182 -62 610 755 -19 Other Pharmaceutical (8) 1,796 1,758 2 559 518 8 1,232 1,239 -1 ANIMAL HEALTH 4,480 4,347 3 1,417 1,418 - 3,063 2,929 5 Livestock 2,573 2,530 2 529 543 -3 2,044 1,987 3 Companion Animal 1,907 1,817 5 888 875 1 1,019 942 8 Other Revenues (9) 706 696 2 109 135 -19 597 561 6 *200% or greater (6) Net product sales in Merck's marketing territories. (7) Total Diabetes sales were $2,053 million and $2,826 million on a global basis for September YTD 2024 and 2023, respectively. (8) Includes Pharmaceutical products not individually shown above. (9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $91 million and $118 million on a global basis for September YTD 2024 and 2023, respectively. Sum of U.S. plus international may not equal global due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Alliance Revenue represents royalties. (4) Total Vaccines sales were $10,755 million and $10,692 million on a global basis for September YTD 2024 and 2023, respectively. (5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. 7 -- 8 of 10 -- MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c 2024 2023 % Change 1Q 2Q 3Q Sep YTD 1Q 2Q 3Q Sep YTD 4Q Full Year 3Q Sep YTD TOTAL PHARMACEUTICAL $14,006 $14,408 $14,943 $43,358 $12,721 $13,457 $14,263 $40,442 $13,141 $53,583 5 7 United States 6,936 7,399 8,227 22,563 6,117 6,570 7,153 19,840 6,698 26,539 15 14 % Pharmaceutical Sales 49.5% 51.4% 55.1% 52.0% 48.1% 48.8% 50.1% 49.1% 51.0% 49.5% Europe (1) 2,555 2,572 2,620 7,748 2,326 2,401 2,497 7,224 2,491 9,715 5 7 % Pharmaceutical Sales 18.2% 17.9% 17.5% 17.9% 18.3% 17.8% 17.5% 17.9% 19.0% 18.1% China 1,744 1,790 996 4,530 1,694 1,887 1,674 5,255 1,456 6,710 -40 -14 % Pharmaceutical Sales 12.5% 12.4% 6.7% 10.4% 13.3% 14.0% 11.7% 13.0% 11.1% 12.5% Japan 802 664 919 2,386 737 652 1,062 2,451 629 3,081 -13 -3 % Pharmaceutical Sales 5.7% 4.6% 6.2% 5.5% 5.8% 4.8% 7.4% 6.1% 4.8% 5.7% Latin America 601 661 730 1,992 470 566 696 1,731 596 2,328 5 15 % Pharmaceutical Sales 4.3% 4.6% 4.9% 4.6% 3.7% 4.2% 4.9% 4.3% 4.5% 4.3% Asia Pacific (other than China and Japan) 580 595 669 1,844 703 705 636 2,045 616 2,661 5 -10 % Pharmaceutical Sales 4.1% 4.1% 4.5% 4.3% 5.5% 5.2% 4.5% 5.1% 4.7% 5.0% Eastern Europe/Middle East/Africa 395 353 400 1,147 381 370 301 1,052 299 1,351 33 9 % Pharmaceutical Sales 2.8% 2.4% 2.7% 2.6% 3.0% 2.7% 2.1% 2.6% 2.3% 2.5% Canada 138 143 133 414 141 127 133 401 138 540 - 3 % Pharmaceutical Sales 1.0% 1.0% 0.9% 1.0% 1.1% 0.9% 0.9% 1.0% 1.1% 1.0% Other 255 231 249 734 152 179 111 443 218 658 124 66 % Pharmaceutical Sales 1.9% 1.6% 1.5% 1.7% 1.2% 1.6% 0.9% 0.9% 1.5% 1.4% Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 3Q24 3Q23 Sep YTD 2024 Sep YTD 2023 Interest income (127) $ (73) $ (269) $ (295) $ Interest expense 330 317 943 836 Exchange losses 33 85 177 208 Loss (income) from investments in equity securities, net (1) 31 33 (169) (240) Net periodic defined benefit plan (credit) cost other than service cost (157) (138) (476) (364) Other, net (272) (98) (357) 243 Total (162) $ 126 $ (151) $ 388 $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --